AU2001289751A1 - Selective pde 2 inhibitors, used as medicaments for improving cognition - Google Patents

Selective pde 2 inhibitors, used as medicaments for improving cognition

Info

Publication number
AU2001289751A1
AU2001289751A1 AU2001289751A AU8975101A AU2001289751A1 AU 2001289751 A1 AU2001289751 A1 AU 2001289751A1 AU 2001289751 A AU2001289751 A AU 2001289751A AU 8975101 A AU8975101 A AU 8975101A AU 2001289751 A1 AU2001289751 A1 AU 2001289751A1
Authority
AU
Australia
Prior art keywords
medicaments
inhibitors
selective pde
improving cognition
cognition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289751A
Inventor
Frank-Gerhard Boss
Martin Hendrix
Gerhard Konig
Ulrich Niewohner
Dagmar Schauss
Karl-Heinz Schlemmer
Rudy Schreiber
Franz-Josef Van Der Staay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122893A external-priority patent/DE10122893A1/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2001289751A1 publication Critical patent/AU2001289751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2001289751A 2000-08-01 2001-07-19 Selective pde 2 inhibitors, used as medicaments for improving cognition Abandoned AU2001289751A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE10037411 2000-08-01
DE10037411 2000-08-01
DE10037411.5 2000-08-01
DE10122893 2001-05-11
DE10122893A DE10122893A1 (en) 2000-08-01 2001-05-11 Selective PDE 2 inhibitors as medicines to improve perception
DE10122893.7 2001-05-11
PCT/EP2001/008609 WO2002009713A2 (en) 2000-08-01 2001-07-19 Selective pde 2 inhibitors, used as medicaments for improving cognition

Publications (1)

Publication Number Publication Date
AU2001289751A1 true AU2001289751A1 (en) 2002-02-13

Family

ID=26006577

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289751A Abandoned AU2001289751A1 (en) 2000-08-01 2001-07-19 Selective pde 2 inhibitors, used as medicaments for improving cognition

Country Status (7)

Country Link
US (1) US7022709B2 (en)
EP (1) EP1307201B1 (en)
JP (1) JP2004505054A (en)
AU (1) AU2001289751A1 (en)
CA (1) CA2417631A1 (en)
ES (1) ES2233685T3 (en)
WO (1) WO2002009713A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158738A0 (en) * 2001-05-09 2004-05-12 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
JP2006508030A (en) 2002-05-09 2006-03-09 サイトキネティクス・インコーポレーテッド Pyrimidinone compounds, compositions and methods
DE10232113A1 (en) 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
DE10238722A1 (en) * 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
DE10238723A1 (en) * 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
DE102004004142A1 (en) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
DE10320785A1 (en) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-arylmethyl substituted pyrazolopyrimidines
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
JP2006525966A (en) * 2003-05-09 2006-11-16 バイエル・ヘルスケア・アクチェンゲゼルシャフト 6-cyclylmethyl- and 6-alkylmethyl substituted pyrazolopyrimidines
DE10328479A1 (en) 2003-06-25 2005-01-13 Bayer Ag 6-arylamino-5-cyano-4-pyrimidinones
US20060229242A1 (en) * 2003-08-28 2006-10-12 Altana Phazma Ag Composition comprising a pulmonary surfactant and a pde2 inhibitor
DE102004001873A1 (en) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2414363E (en) 2009-03-31 2014-02-26 Boehringer Ingelheim Int 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
UA110347C2 (en) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Derivative 6-cycloalkanes 1.5 dyhidropirazol [3,4-d] pyrimidine-4-one and their use as inhibitors pde9a
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
MX361539B (en) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound.
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co Heterocyclic compound
WO2015002230A1 (en) 2013-07-03 2015-01-08 武田薬品工業株式会社 Amide compound
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
CA2969597C (en) 2014-12-06 2023-10-24 Intra-Cellular Therapies, Inc. 1h-pyrazolo[4,3-c][1,5]naphthyridin-4(5h)-one compounds and their use as pde2 inhibitors
AU2015357496B2 (en) 2014-12-06 2019-09-19 Intra-Cellular Therapies, Inc. Organic compounds
WO2017000276A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
MX2019007803A (en) 2016-12-28 2019-08-29 Dart Neuroscience Llc Substituted pyrazolopyrimidinone compounds as pde2 inhibitors.
MA53841A (en) 2017-06-08 2021-09-22 Merck Sharp & Dohme PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
ES2902365T3 (en) 2017-11-27 2022-03-28 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816995A1 (en) * 1988-05-19 1989-11-23 Hoechst Ag USE OF PYRIMIDO- (6,1-A) -ISOCHINOLIN-4-ON-DERIVATIVES AND MEDICAL PREPARATIONS BASED ON THESE COMPOUNDS
DE19541264A1 (en) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-one derivatives
DE19709877A1 (en) * 1997-03-11 1998-09-17 Bayer Ag 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
DE19838705A1 (en) * 1998-08-26 2000-03-02 Bayer Ag New dihydro- (1,2,3) -triazolo- [4,5-d] pyrimidin-7-ones
WO2000024745A1 (en) * 1998-10-23 2000-05-04 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
CA2395418A1 (en) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
US6683081B2 (en) * 1999-12-24 2004-01-27 Bayer Aktiengesellschaft Triazolotriazinones and the use thereof
AU781028B2 (en) * 1999-12-24 2005-04-28 Bayer Aktiengesellschaft Imidazo (1,3,5) triazinones and the use thereof

Also Published As

Publication number Publication date
WO2002009713A2 (en) 2002-02-07
EP1307201A2 (en) 2003-05-07
JP2004505054A (en) 2004-02-19
EP1307201B1 (en) 2004-11-24
ES2233685T3 (en) 2005-06-16
US7022709B2 (en) 2006-04-04
US20020132754A1 (en) 2002-09-19
CA2417631A1 (en) 2003-01-29
WO2002009713A3 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
HUP0301742A3 (en) Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
AU2002221827A1 (en) Novel lactame-substituted pyrazolopyridine derivatives
AU2002216028A1 (en) Novel carbamate-substituted pyrazolopyridine derivatives
AU6383101A (en) Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
AU2001241056A1 (en) Spiro compounds, process for preparing the same and use thereof as drugs
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
AU2001242364A1 (en) Process for the epoxidation of olefins
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
AU2001273762A1 (en) Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
AU2001292331A2 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2000254308A1 (en) Pyrazolopyrimidinone derivatives, process for their preparation and their use
AU2002210632A1 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
AU2002306687A1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU2001258200A1 (en) Synthetic derivatives of lunularic acid, medicaments containing said compounds, method for producing the lunularic acid derivatives and the use thereof
PL369718A1 (en) Process for the preparation of (1,4,5)-oxadiazepine derivatives
AU2001293697A1 (en) N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
HUP0303110A3 (en) 5-amino-1-pentene-3-ol substituted derivatives, process for their preparation and pharmaceutical compositions containing them and their use
AU2001235448A1 (en) Process for the epoxidation of olefins